Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics for fibrotic diseases, solid tumors and muscular dystrophies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Pliant’s clinical programs and corporate strategy evolve over time.
In its recent press releases, Pliant has highlighted several key themes. The company has reported interim and ongoing data from a Phase 1, open-label, dose-escalation trial of PLN-101095, an oral dual-selective inhibitor of integrins αvβ8 and αvβ1, in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors. These updates describe antitumor activity, including partial and complete responses in certain dose cohorts when PLN-101095 is combined with pembrolizumab, as well as safety and pharmacokinetic observations.
Pliant’s news flow has also covered developments in its bexotegrast (PLN-74809) program in idiopathic pulmonary fibrosis, including the termination and close-out of the BEACON-IPF Phase 2b/3 trial and the company’s decision to discontinue development of bexotegrast in IPF after reviewing safety and efficacy data. Additional communications have described scientific presentations at medical conferences, such as the American Thoracic Society International Conference, where the company has shared clinical and preclinical data related to fibrosis and biomarkers.
Corporate updates, including workforce and operational realignments, financial results and changes in executive roles, are also part of Pliant’s news record. Investors and followers of PLRX can use this page to review these categories of news—clinical trial updates, scientific presentations, program decisions and corporate announcements—in one place and revisit past disclosures as needed.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology company focused on fibrosis therapies, will participate in two investor conferences in September 2022. The conferences are Citi's 17th Annual BioPharma Conference from September 6-7, and H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, where a pre-recorded fireside chat will be accessible on September 12 at 7:00 a.m. ET. Pliant's lead product candidate, PLN-74809, is under Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received various designations from the FDA and EMA.
Pliant Therapeutics (PLRX) reported second quarter 2022 financial results and highlighted progress in its clinical trials. The INTEGRIS-IPF Phase 2a trial for PLN-74809 showed positive safety and efficacy data, achieving its primary endpoint with dose-dependent treatment effects in patients with idiopathic pulmonary fibrosis. The company received FDA Fast Track designation for PLN-74809 in treating primary sclerosing cholangitis. Financially, R&D expenses increased to $26.3 million, while the net loss rose to $29.5 million, attributed to higher operating costs. Cash reserves stand at $379.8 million post-fundraising.
Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology company, announced that Dr. Bernard Coulie will participate in a panel on drug development in pulmonary medicine at the BTIG Biotechnology Conference 2022. The event is scheduled for August 9, 2022, at 1:00 p.m. ET. Pliant is focused on developing therapies for fibrosis, with its lead candidate, PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The panel discussion will be available via the BTIG portal for registered participants.
Pliant Therapeutics (NASDAQ: PLRX) has announced that its lead drug candidate, PLN-74809, received Fast Track designation from the FDA for treating primary sclerosing cholangitis (PSC). This designation aims to expedite the drug's development due to the disease’s severity and lack of FDA-approved therapies. PLN-74809 is currently in the Phase 2a INTEGRIS-PSC trial, with topline data expected in the first half of 2023. PSC affects over 30,000 patients in the U.S. alone, highlighting a significant unmet medical need.
Pliant Therapeutics, a clinical-stage biotechnology company, has successfully completed an upsized underwritten public offering of 12,432,432 shares at $18.50 each, generating approximately $230 million in gross proceeds. The offering included the full exercise of the underwriters' option for additional shares. Pliant intends to utilize the net proceeds to advance ongoing and future clinical programs, including PLN-74809, as well as to support working capital and general corporate purposes. J.P. Morgan and Cowen acted as lead book-running managers for this offering.
Pliant Therapeutics (PLRX) announced the pricing of an upsized underwritten public offering of 10,810,811 shares at $18.50 each, aiming to raise approximately $200 million. The offering is set to close around July 15, 2022. The proceeds will support ongoing and future clinical programs, working capital, operating expenses, and capital expenditures. Underwriters have an option for an additional 1,621,621 shares. The offering is conducted under a previously effective SEC registration statement.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced a public offering of $150 million in common stock, with an optional $22.5 million for underwriters. The funds will support ongoing and future clinical programs, including PLN-74809, operational expenses, and development of their integrin targeting platform. The offering is subject to market conditions and regulatory approvals. J.P. Morgan and Cowen are leading the offering, with RBC Capital Markets acting as a book-running manager.
Pliant Therapeutics announced positive results from the INTEGRIS-IPF Phase 2a trial of PLN-74809 for idiopathic pulmonary fibrosis (IPF). The trial met its primary and secondary endpoints over 12 weeks, demonstrating a favorable safety profile with no drug-related serious adverse events. Notably, PLN-74809 showed a dose-dependent treatment effect, achieving an 80% reduction in forced vital capacity (FVC) decline compared to placebo. 97% of patients completed the trial without discontinuations due to adverse effects. The company plans to share results with regulatory authorities and anticipates interim data from an additional cohort in early 2023.
Pliant Therapeutics (PLRX) presented significant findings on its antifibrotic candidate, PLN-74809, at the International Liver Congress 2022. The posters highlighted the oral dual integrin inhibitor's favorable tolerability in the INTEGRIS-PSC study and its preclinical efficacy in reducing fibrosis markers in biliary fibrosis models. Results indicated dose-dependent reductions in liver fibrosis and TGF-β signaling, positioning PLN-74809 as a promising treatment for primary sclerosing cholangitis (PSC) and idiopathic pulmonary fibrosis (IPF). The ongoing Phase 2a trials aim to further evaluate the drug's impact.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has presented promising preclinical data for PLN-101325, an allosteric antibody targeting the α7β1 integrin, at the New Directions in Biology and Disease of Skeletal Muscle Conference. The data indicates improved muscle function in dystrophic conditions, particularly in diaphragm strength, which could lead to better treatments for muscular dystrophies like Duchenne Muscular Dystrophy (DMD). An IND submission for PLN-101325 is expected by the end of 2022, with clinical trials anticipated to commence in early 2023.